How to buy Xenon Pharmaceuticals stock | $11.72

Xenon Pharmaceuticals Inc is a biotechnology business based in the US. Xenon Pharmaceuticals shares (XENE) are listed on the NASDAQ and all prices are listed in US Dollars. Xenon Pharmaceuticals employs 100 staff and has a trailing 12-month revenue of around USD$30.3 million.

How to buy shares in Xenon Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Xenon Pharmaceuticals. Find the stock by name or ticker symbol: XENE. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Xenon Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$11.72, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Xenon Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Xenon Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Xenon Pharmaceuticals share price

Use our graph to track the performance of XENE stocks over time.

Xenon Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-12-02.

Latest market close	USD$11.72
52-week range	USD$7 - USD$18.1
50-day moving average	USD$10.8886
200-day moving average	USD$11.7765
Wall St. target price	USD$23
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.717

Buy Xenon Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Xenon Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Xenon Pharmaceuticals Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Xenon Pharmaceuticals price performance over time

Historical closes compared with the close of $11.72 from 2020-12-09

1 week (2021-01-05)	-16.05%
1 month (2020-12-12)	N/A
3 months (2020-10-12)	1.47%
6 months (2020-07-12)	N/A

1 year (2020-01-12)	N/A
2 years (2019-01-12)	N/A
3 years (2018-01-12)	304.14%
5 years (2016-01-12)	45.95%

Xenon Pharmaceuticals financials

Revenue TTM	USD$30.3 million
Gross profit TTM	USD$-32,016,000
Return on assets TTM	-12.57%
Return on equity TTM	-21.74%
Profit margin	-91.91%
Book value	$4.98
Market capitalisation	USD$410.3 million

TTM: trailing 12 months

Shorting Xenon Pharmaceuticals shares

There are currently 806,384 Xenon Pharmaceuticals shares held short by investors – that's known as Xenon Pharmaceuticals's "short interest". This figure is 11.9% up from 720,710 last month.

There are a few different ways that this level of interest in shorting Xenon Pharmaceuticals shares can be evaluated.

Xenon Pharmaceuticals's "short interest ratio" (SIR)

Xenon Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Xenon Pharmaceuticals shares currently shorted divided by the average quantity of Xenon Pharmaceuticals shares traded daily (recently around 119641.54302671). Xenon Pharmaceuticals's SIR currently stands at 6.74. In other words for every 100,000 Xenon Pharmaceuticals shares traded daily on the market, roughly 6740 shares are currently held short.

However Xenon Pharmaceuticals's short interest can also be evaluated against the total number of Xenon Pharmaceuticals shares, or, against the total number of tradable Xenon Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xenon Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Xenon Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0237% of the tradable shares (for every 100,000 tradable Xenon Pharmaceuticals shares, roughly 24 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Xenon Pharmaceuticals.

Find out more about how you can short Xenon Pharmaceuticals stock.

Xenon Pharmaceuticals share dividends

We're not expecting Xenon Pharmaceuticals to pay a dividend over the next 12 months.

Xenon Pharmaceuticals share price volatility

Over the last 12 months, Xenon Pharmaceuticals's shares have ranged in value from as little as $7 up to $18.1. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenon Pharmaceuticals's is 1.336. This would suggest that Xenon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Xenon Pharmaceuticals overview

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is Phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in Phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase I clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop first-in-class treatments for epilepsy. The company was founded in 1996 and is headquartered in Burnaby, Canada.

Frequently asked questions

• What percentage of Xenon Pharmaceuticals is owned by insiders or institutions?

  Currently 6.57% of Xenon Pharmaceuticals shares are held by insiders and 81.266% by institutions.

• How many people work for Xenon Pharmaceuticals?

  Latest data suggests 100 work at Xenon Pharmaceuticals.

• When does the fiscal year end for Xenon Pharmaceuticals?

  Xenon Pharmaceuticals's fiscal year ends in December.

• Where is Xenon Pharmaceuticals based?

  Xenon Pharmaceuticals's address is: 200 ? 3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8

• What is Xenon Pharmaceuticals's ISIN number?

  Xenon Pharmaceuticals's international securities identification number is: CA98420N1050

• What is Xenon Pharmaceuticals's CUSIP number?

  Xenon Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 98420N105